实体器官移植后难治性/耐药性巨细胞病毒感染诊疗进展

Progression in diagnosis and treatment of refractory/resistant cytomegalovirus infection after solid organ transplantation

随着我国实体器官移植(SOT)事业的飞速发展,巨细胞病毒(CMV)感染的发病人数日益增多。其中,耐药性和难治性CMV感染的发病率也逐渐升高,导致SOT受者的死亡率显著增加,值得临床高度关注。随着新的诊断技术出现和新药的研发上市,难治性/耐药性CMV感染的诊疗不断发展。本文总结了SOT受者难治性CMV感染的诊治新进展,包括难治性/耐药性CMV感染的定义、诊断以及治疗策略,旨在为预防和治疗SOT后难治性/耐药性CMV感染提供参考。

With the rapid development of solid organ transplantation(SOT)in China,the number of people infected with cytomegalovirus(CMV)is increasing.The incidence rate of resistant CMV and refractory CMV infection is also increasing,leads to the mortality increase significantly,which require clinical attention.Along with improvement of the new diagnostic technologies and new drugs,the diagnosis and treatment of refractory/resistant CMV infection continue to improve.This review summarizes the new progress in the diagnosis and treatment strategies on refractory CMV infection in SOT recipients,including the definition,the diagnosis and treatment strategies.The article is aimed to provide references for prevention and treatment of refractory/drug resistant CMV infection in organ transplant recipients.